Prevention and restoration of hearing loss associated with the use of cisplatin
Related Experiment Video
Updated: Apr 25, 2026
Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
Published on: March 16, 2018
Felician Chirtes1, Silviu Albu2
1Otolaryngology Department, Military Hospital Cluj-Napoca, 22 General Traian Mosoiu Street, 3400 Cluj-Napoca, Romania.
Background:
Cisplatin is a well known platinum-based chemotherapeutic agent used for the treatment of various malignant tumours. A frequent side effect of cisplatin therapy is ototoxicity. Unfortunately, currently there are no available treatments.
Material And Methods:
Experimental, clinical studies and reviews published between 2004 and 2014 in the English medical literature concerning ototoxicity were selected using Medline, PubMed, and Google Scholar databases. Inclusion criteria were cisplatin-induced ototoxicity and therapy aimed at preventing or curing this disorder. Molecular mechanisms and clinical, audiological, and histological markers of cisplatin-induced ototoxicity are described. Moreover, experimental and clinical strategies for prevention or treatment of hearing loss were also reviewed.
Results And Discussion:
Experimental studies demonstrate a wide range of otoprotective molecules and strategies efficient against cisplatin-induced hearing loss. However, only dexamethasone proved a slight otoprotective effect in a clinical study.
Conclusion:
Further research must be completed to bring future therapeutic options into clinical setting.
